摘要
目的研究肾移植术后患者MDR1C3435T基因多态性对他克莫司(FK506)血药浓度/剂量比(C/D)及急性排斥反应和不良反应的影响。方法采用聚合酶链反应(PCR)和限制性内切片段长度多态性(RFLP)的方法检测肾移植患者MDR1C3435T基因型,比较不同基因型患者之间FK506的C/D值以及急性排斥反应、不良反应的差异。结果MDR1C3435T各基因型组间FK506的C/D值及急性排斥反应、不良反应均无显著性差异。结论MDR1C3435T基因多态性与肾移植患者FK506的C/D值及急性排斥反应、不良反应间无显著相关性。
Objective To investigate the impact of MDRIC3435T genetic polymorphism on the concentration/dose（C/D） ratio, acute rejection and adverse effect of taerolimus （FK506）in the renal patients after transplantation. Methods The MDR1 C3435T genotype was determined by PCR-RFLP method. The differences of C/D ratio, acute rejection and adverse reaction were compared among all of the genotype groups treated with FK506. Results There was no significant difference in the C/D ratio, rejection and adverse reaction of FK506 among MDR1 C3435 T genotype groups. Conclusion There was no significant relation between the C/D ratio, acute rejection and adverse reaction of FK506 and MDR163435 T genetic polymorphism in the transplant patients.
出处
《药学实践杂志》
CAS
2010年第1期29-31,共3页
Journal of Pharmaceutical Practice
